Cannabis Stocks Surge After President Trump Endorses Cannabidiol for Senior Healthcare

Shares of major cannabis companies soared on September 29, 2025, following President Donald Trump’s unexpected endorsement of hemp-derived cannabidiol (CBD) for senior healthcare in a social media post. This announcement, coming amid ongoing discussions about possible federal reclassification of marijuana, has ignited renewed debate about the role of CBD in medical practice, especially for older adults.

Key Developments

President Trump, in a message to the public, declared that hemp-derived CBD “could revolutionize senior healthcare by helping reduce disease progression” and described it as an alternative to conventional prescription drugs. This statement was made via Truth Social on Sunday, catching policy makers and the healthcare community by surprise. He further suggested that Medicare should consider covering CBD products for seniors, amplifying speculation about potential policy shifts.

The immediate market response was dramatic:

• Shares of Tilray Brands and Canopy Growth rose nearly 20%.

• Cronos Group gained 9.5%, Aurora Cannabis surged by 13.7%.

• The AdvisorShares Pure U.S. Cannabis ETF saw a 25% jump, poised for its largest quarterly gain on record.

Evidence and Research

CBD, or cannabidiol, is a non-psychoactive compound found in cannabis plants. It has become widely used in recent years for conditions such as chronic pain, insomnia, anxiety, and inflammation. Robust research into its safety and efficacy is still evolving, but a growing body of evidence supports its use in select populations, including older adults.

A 2025 multi-site prospective study, published in a peer-reviewed journal, followed 299 adults over the age of 50 using medical cannabis. Key findings included:

• 90% of participants used cannabis for pain-related conditions.

• Significant improvements were recorded in pain, sleep, and quality of life measures.

• Nearly 50% of participants reported reducing other prescription medications.

• No serious adverse events were reported over the six-month study.

• The incremental cost per quality-adjusted life-year (QALY) for medical cannabis was $25,357.20, which is well below the standard for traditional pharmaceuticals.

However, most patients preferred oral formulations high in CBD and low in THC, reflecting current clinical recommendations that favor lower psychoactive risk for elderly populations.

Expert Perspectives

Dr. Prakash Rao, MD, a geriatric medicine specialist with no financial ties to cannabis producers, offered a measured perspective: “We’re seeing promising evidence that CBD may help seniors manage chronic conditions with fewer side effects than some traditional pharmaceuticals. However, rigorous randomized controlled trials are needed before broad recommendations can be made.”

Ben Laidler, head of equity strategy at Bradesco BBI, noted, “Any support from President Trump goes a long way for the cannabis sector, especially one beleaguered by regulatory uncertainty. But medical professionals will rightly call for caution and more research.”

Context and Background

Cannabis for medical purposes is currently legal in 40 U.S. states, and recreational use is permitted in 24 states. Federal restrictions, however, remain a major barrier for both the cannabis industry and patients seeking access.

Globally, older adults represent a swiftly growing subset of medical cannabis users. Surveys from Canada and the U.S. indicate seniors use cannabis primarily for pain, sleep disorders, and reductions in prescription drug use. Recent clinical research shows that high-CBD products can improve quality of life for many seniors, but also highlights the need for more robust dosing guidelines and monitoring for drug interactions, especially in polypharmacy settings.

Implications for Public Health

If federal regulations around cannabis and CBD are eased, millions of older Americans may gain safer and more cost-effective alternatives for chronic pain and other age-related conditions. Potential benefits include:

• Reduced dependence on opioids and benzodiazepines, which carry higher risks of side effects and addiction in seniors.

• Improved quality of life, sleep, and pain management.

• Lower healthcare costs due to decreased prescription drug use.

• However, health authorities stress the importance of individual medical evaluation and professional guidance when exploring CBD therapies. The American Medical Association notes that while CBD is generally well tolerated, potential adverse effects include gastrointestinal symptoms and interactions with certain medications.

• Limitations and Controversies

Despite the positive market reaction, several concerns persist:

• The current regulatory environment is unsettled; President Trump’s comments have not yet translated into actionable policy changes.

• Most available evidence comes from observational studies, not randomized clinical trials.

• Research suggests older adults may experience increased cannabis-related health complications, such as emergency room visits if not properly monitored.

• Industry-funded studies may introduce bias; further independent investigations are required.

Dr. S. Nain, a researcher on aging at the University of Michigan, cautions: “The enthusiasm must be balanced with caution—we still need large-scale randomized studies and long-term safety data, especially as older patients tend to have complex medication profiles and increased vulnerability to adverse effects.”

Practical Advice for Consumers

For seniors or caregivers considering CBD:

• Consult with a qualified healthcare professional first.

• Check product purity and authenticity—buy only from regulated sources.

• Start with low doses and monitor for adverse effects.

• Inform all treating clinicians about CBD use to check for drug interactions.

• Stay updated on shifting regulations and evolving research.

Conclusion

President Trump’s endorsement of CBD as a tool for senior healthcare has spurred significant market and public interest, but medical experts urge skepticism and additional research. For now, CBD remains a potentially valuable adjunct for older adults with chronic conditions, provided its use is evidence-based and medically supervised.

Medical Disclaimer: This article is for informational purposes only and should not be considered medical advice. Always consult with qualified healthcare professionals before making any health-related decisions or changes to your treatment plan. The information presented here is based on current research and expert opinions, which may evolve as new evidence emerges.

References